Twelve‐week, multicenter, placebo‐controlled, randomized, double‐blind, parallel‐group, comparative phase II/III study of benzoyl peroxide gel in patients with acne vulgaris: A secondary publication

• Published in: Journal of dermatology Vol. 44; no. 7; pp. 774 - 782
• Main Authors: Kawashima, Makoto, Sato, Shinichi, Furukawa, Fukumi, Matsunaga, Kayoko, Akamatsu, Hirohiko, Igarashi, Atsuyuki, Tsunemi, Yuichiro, Hayashi, Nobukazu, Yamamoto, Yuki, Nagare, Toshitaka, Katsuramaki, Tsuneo
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.07.2017; John Wiley and Sons Inc
• Subjects: Acne; acne vulgaris; Acne Vulgaris - drug therapy; Administration, Cutaneous; Adolescent; Adult; benzoyl peroxide; Benzoyl Peroxide - pharmacology; Benzoyl Peroxide - therapeutic use; comparative study; Dermatologic Agents - pharmacology; Dermatologic Agents - therapeutic use; Dose-Response Relationship, Drug; Double-Blind Method; Double-blind studies; Erythema - chemically induced; Erythema - epidemiology; Female; Gels - therapeutic use; Humans; Incidence; Inflammation; Japan; Male; Middle Aged; Original; Peroxide; Placebo effect; Placebos; placebo‐controlled; randomized; Skin; Skin - drug effects; Treatment Outcome; Young Adult; acne vulgaris; comparative study; placebo-controlled; benzoyl peroxide; randomized
• ISSN: 0385-2407; 1346-8138; 1346-8138
• DOI: 10.1111/1346-8138.13798

A placebo‐controlled, randomized, double‐blind, parallel‐group, comparative, multicenter study was conducted to investigate the efficacy and safety of benzoyl peroxide (BPO) gel, administrated once daily for 12 weeks to Japanese patients with acne vulgaris. Efficacy was evaluated by counting all inflammatory and non‐inflammatory lesions. Safety was evaluated based on adverse events, local skin tolerability scores and laboratory test values. All 609 subjects were randomly assigned to receive the study products (2.5% and 5% BPO and placebo), and 607 subjects were included in the full analysis set, 544 in the per protocol set and 609 in the safety analyses. The median rates of reduction from baseline to the last evaluation of the inflammatory lesion counts, the primary end‐point, in the 2.5% and 5% BPO groups were 72.7% and 75.0%, respectively, and were significantly higher than that in the placebo group (41.7%). No deaths or other serious adverse events were observed. The incidences of adverse events in the 2.5% and 5% BPO groups were 56.4% and 58.8%, respectively; a higher incidence than in the placebo group, but there was no obvious difference between the 2.5% and 5% BPO groups. All adverse events were mild or moderate in severity. Most adverse events did not lead to study product discontinuation. The results suggested that both 2.5% and 5% BPO are useful for the treatment of acne vulgaris.